Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?

Amir Azarbal, Leonardo Clavijo, Michael A. Gaglia

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.

Original languageEnglish (US)
Pages (from-to)144-156
Number of pages13
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume20
Issue number2
DOIs
StatePublished - Mar 14 2015
Externally publishedYes

Keywords

  • antiplatelet therapy
  • aspirin
  • clopidogrel
  • critical limb ischemia
  • peripheral arterial disease heart disease

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?'. Together they form a unique fingerprint.

Cite this